BALL KRISTINE M 4

What Happened

• Kristine M. Ball, a director of Oruka Therapeutics (ORKA), received a derivative award on June 2, 2026 covering 9,136 shares. The Form 4 reports an acquisition price of $0.00 and a total reported value of $0.
• The footnote clarifies this is an option that vests as to 1/12 of the underlying shares monthly beginning June 2, 2026 (i.e., a 12-month monthly vesting schedule).

Key Details

• Transaction date: 2026-06-02; Report filed: 2026-06-03 (timely filing).
• Transaction type/code: Award/Grant (A) of a derivative instrument (option) covering 9,136 shares; reported acquisition price $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Option vests 1/12 monthly from June 2, 2026.
• No indication this was a sale or market purchase—this is a compensation grant.

Context

• This was a compensation grant (an option award) to a director. Such awards are common for directors and are not the same as an open-market purchase or sale; they represent potential future ownership if and when options vest and are exercised.
• The monthly vesting means portions of the award become exercisable over the following 12 months rather than all at once.